Geode Capital Management
RNAZ icon

Geode Capital Management’s TransCode Therapeutics RNAZ Stock Holding History

Geode Capital Management’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,740
Closed -$110K – 4542
2026
Q1 		$110K Buy
+12,740
New +$119K ﹤0.01% 4111
2024
Q4 		– Sell
-132
Closed -$69.5K – 4501
2024
Q3 		$69.5K Buy
132
+90
+214% +$36.4K ﹤0.01% 4193
2024
Q2 		$38.6K Buy
+42
New +$37.4K ﹤0.01% 4332
2024
Q1 		– Sell
-1
Closed -$8.61K – 4633
2023
Q4 		$8.61K Buy
+1
New +$11.2K ﹤0.01% 4600
2023
Q2 		– Hold
0
– -$25.6K – 4779
2023
Q1 		– Hold
0
– – – 4657
2022
Q4 		– Hold
0
– – – 4586
2022
Q3 		– Hold
0
– – – 4631
2022
Q2 		– Hold
0
– – – 4610
2022
Q1 		– Hold
0
– – – 4370
2021
Q4 		– Hold
0
– – – 4521
2021
Q3 		– Hold
0
– – – 4779

Other funds holding RNAZ

YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Geode Capital Management's RNAZ Position: Q2 2026 in Review

Geode Capital Management sold out of TransCode Therapeutics (RNAZ) in Q2 2026, closing a stake of 12,740 shares — an estimated $110K sold.

Geode Capital Management first reported a position in RNAZ in Q4 2023 and held it in 4 quarters. The position peaked at $110K in Q1 2026. 8 funds tracked by Wall St. Rank hold RNAZ as of Q2 2026.

  • Geode Capital Management reported no remaining TransCode Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Geode Capital Management sold 12,740 TransCode Therapeutics shares in Q2 2026, an estimated $110K.
  • Geode Capital Management first reported a position in TransCode Therapeutics in Q4 2023 and held it in 4 quarters.
  • Geode Capital Management's TransCode Therapeutics position peaked at $110K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.